Placebo Administration

Phase 3

Placebo Administration is one of 156 therapeutic programs targeting Central Nervous System Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

155

Competitors

Pipeline

Status by Indication[2][1]

Indication

Central Nervous System CancerActive, not recruiting

Prostate CarcinomaActive, not recruiting

Pancreatic Acinar Cell CarcinomaRecruiting

MelanomaActive, not recruiting

Acute Myeloid LeukemiaRecruiting

Clinical Stage IV Cutaneous Melanoma AJCC V8Terminated

Astrocytoma, IDH-Mutant, Grade 3Recruiting

Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC V8Recruiting

Oligometastatic Prostate CarcinomaActive, not recruiting

Barrett EsophagusRecruiting

Central Nervous System CancerPhase 3

Active, not recruiting

Prostate CarcinomaPhase 3

Active, not recruiting

Pancreatic Acinar Cell CarcinomaPhase 2

Recruiting

MelanomaPhase 2

Active, not recruiting

Acute Myeloid LeukemiaPhase 3

Recruiting

Clinical Stage IV Cutaneous Melanoma AJCC V8Phase 2

Terminated

Astrocytoma, IDH-Mutant, Grade 3Phase 3

Recruiting

Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC V8Phase 2

Recruiting

Oligometastatic Prostate CarcinomaPhase 2

Active, not recruiting

Barrett EsophagusPhase 2

Recruiting

Showing 10 of 11 indications

Competition

Competitive Landscape

947 competitors in Melanoma

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

98 2

Opdivo

Libtayo

6 4

Placebo Administration

RRoswell Park Cancer Institute

Phase 3

1 5

Peg-IFN Alfa-2b

Merck & Co.

Phase 3

1 6

GSK2118436

GSK

Phase 3

1 7

Zelboraf

CConrado Roberto Hoffmann Filho

Preclinical

39 8

Intron a

Merck & Co.

Preclinical

4 9

Opdualag

Bristol-Myers Squibb

Preclinical

3 10

PEG-Intron

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Melanoma

NCT05111574

Q1 2027

Phase 2Recruiting

Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC V8

NCT06532279

Q3 2027

Phase 3Active, not recruiting

Central Nervous System Cancer

NCT04939597

Q4 2027

Phase 2Recruiting

Pancreatic Acinar Cell Carcinoma

NCT04858334

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia2 trials

A Randomized Double-Blinded Trial of Xylitol Dental Wipes for the Prophylaxis of Bloodstream Infections From Oral Organisms in Pediatric Patients With Acute Myeloid Leukemia

Recruiting·CChildren's Oncology Group·Phase 3·NCT07022678·556 enrolled

Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT05564390·2,000 enrolled

Barrett Esophagus1 trial

Repurposing Itraconazole for Secondary Prevention of Metaplasia and Primary Prevention of Cancer in Patients With High-risk Barrett's Esophagus in Combination With Ablation

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT06732388·76 enrolled

Central Nervous System Cancer1 trial

A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors

Active, not recruiting·CChildren's Oncology Group·Phase 3·NCT04939597·162 enrolled

Clinical Stage IV Cutaneous Melanoma AJCC v81 trial

The BAMM2 (BRAF, Autophagy, MEK Inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib With or Without Hydroxychloroquine in Advanced BRAF V600E/K Melanoma With Elevated LDH

Terminated·EECOG-ACRIN Cancer Research Group·Phase 2·NCT04527549·5 enrolled

Astrocytoma, IDH-Mutant, Grade 31 trial

Phase III Trial of Radiotherapy Followed by Adjuvant Temozolomide in Combination With the IDH Inhibitor Vorasidenib vs Placebo in IDH-Mutated Newly-Diagnosed Grade 3 Astrocytomas

Recruiting·AAlliance for Clinical Trials in Oncology·Phase 3·NCT07215910·408 enrolled

6 more indications

Pancreatic Acinar Cell Carcinoma1 trial

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04858334·152 enrolled

Prostate Carcinoma1 trial

A Phase III Double Blinded Study of Early Intervention After RADICAl ProstaTEctomy With Androgen Deprivation Therapy With or Without Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)

Active, not recruiting·EECOG-ACRIN Cancer Research Group·Phase 3·NCT04484818·27 enrolled

Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v81 trial

A Randomized, Masked, Placebo Controlled, Phase II Trial Of Concurrent Chemoradiation With BMX-001 In Patients With Head And Neck Squamous Cell Carcinoma Receiving Concurrent Chemoradiation

Recruiting·NNRG Oncology·Phase 2·NCT06532279·98 enrolled

Oligometastatic Prostate Carcinoma1 trial

A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadiotHErapy With or Without ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean)

Active, not recruiting·NNRG Oncology·Phase 2·NCT05053152·194 enrolled

Melanoma1 trial

A Randomized Phase II Trial of Adjuvant Nivolumab With or Without Cabozantinib in Patients With Resected Mucosal Melanoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT05111574·101 enrolled

Cannabis Dependence1 trial

Acute Effects of Sequential Nicotine Vaping on the Pharmacokinetic and Pharmacodynamic Properties of Vaped THC: A Double-Blind, Placebo-Controlled, Randomized Within-Subject Crossover Study

Not yet recruiting·RRoswell Park Cancer Institute·Phase 1·NCT06334016·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for Placebo Administration. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Placebo Administration. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Roswell Park Cancer Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: RRoswell Park Cancer Institute

Placebo Administration

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q1 2027

Q3 2027

Q4 2027

Trials by Indication[1]

Acute Myeloid Leukemia2 trials

Barrett Esophagus1 trial

Central Nervous System Cancer1 trial

Clinical Stage IV Cutaneous Melanoma AJCC v81 trial

Astrocytoma, IDH-Mutant, Grade 31 trial

Pancreatic Acinar Cell Carcinoma1 trial

Prostate Carcinoma1 trial

Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v81 trial

Oligometastatic Prostate Carcinoma1 trial

Melanoma1 trial

Cannabis Dependence1 trial

References

Drug Info

Quick Facts

Related News